Sugi Predict

Sugi Predict / Compounds / SCHEMBL20134970

SCHEMBL20134970

SCHEMBL20134970

Cc1ccc(-n2cc(C3CCN(C(=O)c4ccc([C@@]5(C)NC(=O)NC5=O)cc4)CC3)cn2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ EGLN1 Q9GZT9 1/20 0.39
▸ UBE2M P61081 1/20 0.38
▸ DCUN1D1 Q96GG9 1/20 0.38
▸ ADAMTS5 Q9UNA0 3/20 0.37
▸ ADAM17 P78536 1/20 0.37
▸ MAPK7 Q13164 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ MMP2 P08253 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ CRBN Q96SW2 2/20 0.37
▸ ADAMTS7 Q9UKP4 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ PAK1 Q13153 1/20 0.35
▸ PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134973 1.00 MGLL (0.39) MGLLMEN1KMT2AEGLN1UBE2M
SCHEMBL20135436 0.88 ADAMTS5 (0.39) MGLLMEN1KMT2AEGLN1UBE2M
SCHEMBL20135434 0.88 ADAMTS5 (0.39) MGLLMEN1KMT2AEGLN1UBE2M
SCHEMBL20134838 0.88 ADAMTS5 (0.42) MGLLMEN1KMT2AEGLN1UBE2M
SCHEMBL20134839 0.88 ADAMTS5 (0.42) MGLLMEN1KMT2AEGLN1UBE2M
SCHEMBL20135362 0.84 UBE2M (0.39) MGLLMEN1KMT2AUBE2MDCUN1D1
SCHEMBL20135363 0.84 UBE2M (0.39) MGLLMEN1KMT2AUBE2MDCUN1D1
SCHEMBL20134774 0.80 UBE2M (0.39) MGLLMEN1KMT2AEGLN1UBE2M
SCHEMBL20134773 0.80 UBE2M (0.39) MGLLMEN1KMT2AEGLN1UBE2M
SCHEMBL20134876 0.79 MEN1 (0.65) MGLLMEN1KMT2AALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 — — CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MGLL 3850/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MGLL 3743/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.